← Leaderboards
Glenn D Prestwich
University Of Utah
$4,595,533
Attributed
$6,621,578
Total exposure
15
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $814.8K · FY2005–16$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$6,621,578 · 15
By mechanism
R01$3,144,873 · 2
R44$1,507,000 · 1
R43$1,207,438 · 6
R41$300,000 · 3
R42$247,267 · 1
S10$215,000 · 1
Top collaborators
- Justin Rodney Savage6 shared
- Thomas Preston Kennedy5 shared
- Maria E Ryan4 shared
- Won Yong Lee3 shared
- Narayanam Venkateswara Rao3 shared
- Jeremiah Andrew Alt1 shared
- Balamurali K Ambati1 shared
- Ying Gu1 shared
Others in their field
Top investigators on “Receptor”
- Barton F Haynes · Duke University$182,835,224
- James C. Paulson · Scripps Research Institute$84,068,192
- Asrar B. Malik · University Of Illinois At Chicago$55,280,031
- Anthony O Caggiano · Cognition Therapeutics, Inc.$49,563,751
- Robert J Coffey · Vanderbilt University$48,115,270
- Robert H Vonderheide · University Of Pennsylvania$48,030,034
Research focus
ReceptorChemical SynthesisAnti-InflammatoryIn VivoGlycosaminoglycansAnti-Inflammatory AgentsAdvanced Glycosylation End ProductsChronicPharmaceutical PreparationsInflammationAffinity LabelingLigandsMediatingInflammatoryHyaluronic AcidIn VitroTissuesFamilyMonoclonal AntibodyPhosphatidylinositolsLeadAmericanDoseBase
Grant awards (30)
A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis$297,614
R43 · FY2016 · AI
Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis$7,000
R44 · FY2015 · DE
Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis$685,157
R44 · FY2014 · DE
Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis$814,843
R44 · FY2013 · DE
Novel Glycosaminoglycan Ethers for Prevention of Metastasis$210,000
R43 · FY2011 · CA
Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis$210,000
R43 · FY2011 · DE
Novel Glycosaminoglycan Derivatives for Treatment of Bladder Inflammation$200,024
R43 · FY2011 · DK
Sulfated Polysaccharide Derivatives for the Treatment of Rosacea$149,800
R43 · FY2009 · AR
Sulfated Polysaccharide Derivatives for Treatment of Macular Degeneration$140,000
R43 · FY2009 · EY
Phosphoinositide and Inositol Polyphosphate Probes$316,950
R01 · FY2007 · NS · contact PI
Phosphoinositide and Inositol Polyphosphate Probes$326,417
R01 · FY2006 · NS · contact PI
Phosphoinositide and Inositol Polyphosphate Probes$335,200
R01 · FY2005 · NS
Biomaterials for Adhesion-Free Tendon Repair$51,334
R41 · FY2005 · AR
Biomaterials for Adhesion-Free Tendon Repair$48,666
R41 · FY2005 · AR
Phosphoinositide and Inositol Polyphosphate Probes$345,719
R01 · FY2004 · NS
Thiol-Reactive Crosslinkers for Biomaterials$100,000
R41 · FY2004 · EB
Crosslinkable Hydrogels for Tympanic Membrane Repair$100,000
R41 · FY2004 · DC
AFFINITY PROBES FOR INOSITOL POLYPHOSPHATE RECEPTORS$281,667
R01 · FY2003 · NS
AFFINITY PROBES FOR INOSITOL POLYPHOSPHATE RECEPTORS$274,322
R01 · FY2002 · NS
SQUALENE AND OXIDOSQUALENE CYCLASES$95,582
R01 · FY2002 · GM
CORE--MOLECULAR PHARMACOLOGY$0
P30 · FY2002 · CA
AFFINITY PROBES FOR INOSITOL POLYPHOSPHATE RECEPTORS$305,701
R01 · FY2001 · NS
SQUALENE AND OXIDOSQUALENE CYCLASES$279,578
R01 · FY2001 · GM
CORE--MOLECULAR PHARMACOLOGY$0
P30 · FY2001 · CA
CORE--MOLECULAR PHARMACOLOGY$0
P30 · FY2001 · CA
AFFINITY PROBES FOR INOSITOL POLYPHOSPHATE RECEPTORS$312,025
R01 · FY2000 · NS
SQUALENE AND OXIDOSQUALENE CYCLASES$271,712
R01 · FY2000 · GM
SOLUBLE AND ANTIGENIC PHOSPHOINOSITIDE PHOSPHATES$247,267
R42 · FY2000 · GM
ACQUISTION OF A 300 MHZ NMR SPECTROMETER$215,000
S10 · FY2000 · RR
CORE--MOLECULAR PHARMACOLOGY$0
P30 · FY2000 · CA